Compare Dyne Therapeutics Inc. Common Stock (DYN) vs iShares MSCI Indonesia ETF (EIDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs iShares MSCI Indonesia ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while iShares MSCI Indonesia ETF trades at $11.5 (market cap $398.16M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 7.2× iShares MSCI Indonesia ETF's market cap, and Dyne Therapeutics Inc. Common Stock is more actively traded (3,341,579 versus 1,172,701). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and iShares MSCI Indonesia ETF for 76 Days on average.
| DYN | EIDO | |
|---|---|---|
Market Cap | $2.86B | $398.16M |
Volume | 3,341,579 | 1,172,701 |
Sector | Health | — |
52-Week High | $26.78 | $19.22 |
52-Week Low | $14.60 | $10.80 |
Typical Hold Time | 0 Days | 76 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
EIDO trades at $11.71, up 0.34% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings but faces selling pressure. Recent news highlights declining trading volume and questions about Indonesia's commodity benefits. Financial ratios remain undisclosed in current data.
Outlook remains cautious due to technical downtrend and sector concentration risks. The 44% financials weighting and modest EPS growth limit upside potential. Seasonal patterns may offer brief relief, but structural challenges persist for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →
